ME Therapeutics' Salim Dhanji on making the patient's body the bioreactor
The Vancouver immunologist on myeloid cells as a delivery route, STING for cold tumours, and why in vivo CAR could land near the price of a checkpoint inhibitor.
mRNA
2 stories
Make us preferred on GoogleLatest stories
Page 1 of 1
The primal blueprint: how CamMed mimics evolution to reinvent self-amplifying RNA
CamMed CEO Dr. Ahmet Can Berkyurek on an AI-discovered, single-protein replicase drawn from biology's most ancient machinery — and his case for building it in the UK
